Moreover, compound 18 inhibited GBM cell growth to a greater extent and with long-lasting effects with respect to the reversible analogue 15, evidencing that the irreversible TSPO/MDM2 dual-targeting may represent an interesting alternative to overtake the time-limited effects of traditional drugs for GBM [89]. The gene discussed is TSPO; the disease is glioblastoma.